NEW YORK (GenomeWeb) — Rosetta Genomics said today that it has received final approval from the New York State Department of Health for use of its Rosetta Kidney Cancer Test on patient samples from the state.

Rosetta Genomics has been offering its Kidney Cancer Test in New York under conditional approval since December and now has full approval in all 50 US states.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.